Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.

View Full Paper
Ask AI
Bookmark
Share

Authors

QCQing CaoCMCameron McDonald-HymanJMJoseph Maakaron

Discussion

Loading...

Member takes

Overview

Observational analysis shows low non-relapse mortality and favorable outcomes in elderly patients receiving nonmyeloablative allo-HSCT with graft-versus-host disease prophylaxis.

Key Points

  • Low non-relapse mortality observed at 3.7%, indicating effective transplantation strategies.
  • Overall survival at 2 years was 75%, demonstrating the approach's efficacy in manageable populations.
  • Analysis involved 133 patients receiving nonmyeloablative total body irradiation and post-transplant care.
  • Supports transplantation as a feasible option for frail elderly patients with hematologic malignancies.

Cite This Study

Cao et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d874https://doi.org/10.1182/blood-2025-4220
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.2025
  2. 2T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT2025
  3. 3Outcomes of myeloablative vs reduced and non-myeloablative conditioning in MRD-negative AML and ALL with ptcy-based GVHD prophylaxis2025
  4. 4Effect of post-transplant cyclophosphamide on outcomes in stem cell transplant recipients with myelofibrosis2025
  5. 5Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025